Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Revista Colombiana de Cancerología
versión impresa ISSN 0123-9015
Resumen
LOPERA MARIN, John et al. Replacing procarbazine with etoposide in a new OEPA/COPE treatment scheme in children and adolescents with Hodgkin lymphoma: An evaluation of outcomes in the National Cancer Institute. rev.colomb.cancerol. [online]. 2015, vol.19, n.4, pp.222-228. ISSN 0123-9015. https://doi.org/10.10167j.rccan.2015.11.002.
Purpose: Hodgkin's lymphoma (HL) has an age-standardised incidence of 5.3 cases per 100,000 population, and a cure rate of over 90% of cases. The prognosis depends on multiple factors, the most relevant being: stage, histological type and prognostic indices. It was decided to characterise and evaluate survival outcomes of patients treated with HL in the National Cancer Institute. Patients and methods: A retrospective analysis was performed on a cohort of patients younger than 19 years diagnosed with HL between January 1, 2000 and December 31, 2005, treated in the National Cancer Institute, with emphasis on their demographic, clinical, histopathological, and laboratory characteristics. A descriptive statistical and survival analysis was performed using the Kaplan-Meier log-rank test. A P<.05 was considered statistically significant. Results: The mean follow-up time was 5 years (range: 19 months -11.6 years), and overall and disease free survival was 95% and 83%, respectively, at 5 years. Conclusion: Implementation of an OEPA/COPE treatment protocol in the National Cancer Institute showed good results, as reflected in overall and disease -free survival, exceeding 80%.
Palabras clave : Hodgkin's lymphoma; Children; Treatment.